会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • PARTICLES COMPRISING POLYESTERAMIDE COPOLYMERS FOR DRUG DELIVERY
    • US20140120170A1
    • 2014-05-01
    • US14128731
    • 2012-06-25
    • George MihovJohn Andrew Zupancich
    • George MihovJohn Andrew Zupancich
    • A61K47/34
    • C08G69/44A61K31/165A61K47/34A61K47/6921C08J5/18C08J2377/12C08L77/12Y10T428/2982
    • The present invention relates to micro- or nanoparticles comprising a polyesteramide (PEA) having a chemical formula described by structural formula (IV), Formula (IV) wherein —m+p varies from 0.9-0.1 and q varies from 0.1 to 0.9 —m+p+q=1 whereby m or p could be 0-n is about 5 to about 300; (pref 50-200) —R1 is independently selected from the group consisting of (C2-C20) alkylene, (C2-C20) alkenylene, —(R9—CO—O—R10—O—CO—R9)—, —CHR11—O—CO—R12—COOCR11— and combinations thereof; —R3 and R4 in a single backbone unit m or p, respectively, are independently selected from the group consisting of hydrogen, (C1C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C1-C6)alkyl, —(CH2)SH, —(CH2)2S(CH3), —CH2OH, —CH(OH)CH3, —(CH2)4NH3+, —(CH2)3NHC(═NH2+)NH2, —CH2COOH, —(CH2)COOH, —CH2—CO—NH2, —CH2CH2—CO—NH2, —CH2CH2COOH, CH3—CH2—CH(CH3)—, (CH3)2—CH—CH2—, H2N—(CH2)4—, Ph-CH2—, CH═C—CH2—, HO-p-Ph-CH2—, (CH3)2—CH—, Ph-NH—, NH—(CH2)3—C—, NH—CH═N—CH═C—CH2—. —R5 is selected from the group consisting of (C2-C20)alkylene, (C2-C20)alkenylene, alkyloxy or oligoethyleneglycol —R6 is selected from bicyclic-fragments of 1,4:3,6-dianhydrohexitols of structural formula (III); Formula III —R7 is selected from the group consisting of (C6-C10)aryl (C1-C6)alkyl —R8 is —(CH2)4-; —R9 or R10 are independently selected from C2-C12 alkylene or C2-C12 alkenylene. —R11 or R12 are independently selected from H, methyl, C2-C12 alkylene or C2-C12 alkenylene whereby a is at least 0.05 and b is at least 0.05 and a+b=1.
    • 3. 发明申请
    • FIBER COMPRISING A BIODEGRADABLE POLYMER
    • 包含可生物降解聚合物的纤维
    • US20140179802A1
    • 2014-06-26
    • US14115146
    • 2012-05-02
    • Astrid FrankenGeorge MihovJens Christoph Thies
    • Astrid FrankenGeorge MihovJens Christoph Thies
    • A61K9/00A61K47/34
    • A61K9/0051A61K9/0019A61K9/70A61K47/34C08G69/44D01F1/10D01F6/625D01F6/82D10B2331/02D10B2331/041D10B2401/12
    • The present invention relates to a fiber comprising a biodegradable polymer which undergoes dimensional change upon injection in the human or animal body wherein the dimensional change is a reduction of the surface area to volume ratio of a factor 2 to 10. The fiber is sized for injection via a pharmaceutical syringe needle having a bore of at least 25 Gauge. The biodegradable polymer is an amorphous biodegradable polymer selected from the group of poly-hexamethylene carbonates or polyesteramides. The amorphous biodegradable polymer is a preferably a polyesteramide comprising alpha-amino acids, diols and dicarboxylic acids as building blocks. The invention further relates to the use of the fiber for the manufacturing of a medicament for the treatment of ophthalmic diseases. The invention also relates to a process for the manufacturing of the fiber comprising the following process steps; a. extruding a biodegradable polymer into a fiber fitting in a needle of at least 25 Gauge b. which while under tension is cooled below its glass transition temperature such that the resultant fiber is amorphous.
    • 本发明涉及一种包含生物可降解聚合物的纤维,其在人或动物体内注射时经历尺寸变化,其中尺寸变化是因子2至10的表面积与体积比的降低。纤维的尺寸用于注射 通过具有至少25度的孔的制药注射器针头。 可生物降解的聚合物是选自聚六亚甲基碳酸酯或聚酯酰胺的无定形可生物降解的聚合物。 无定形可生物降解聚合物优选为包含α-氨基酸,二醇和二羧酸作为结构单元的聚酯酰胺。 本发明还涉及该纤维在制备用于治疗眼科疾病的药物中的用途。 本发明还涉及一种用于制造纤维的方法,包括以下工艺步骤; 一个。 将可生物降解的聚合物挤出到至少25巴的针中的纤维配合物中。 其在张力下被冷却到其玻璃化转变温度以下,使得所得纤维是无定形的。
    • 5. 发明申请
    • BIODEGRADABLE POLYESTERAMIDE COPOLYMERS FOR DRUG DELIVERY
    • US20140220099A1
    • 2014-08-07
    • US14128839
    • 2012-06-25
    • Guy DraaismaGeorge Mihov
    • Guy DraaismaGeorge Mihov
    • A61K47/34
    • C08G69/44A61K31/165A61K47/34A61K47/6921C08J5/18C08J2377/12C08L77/12Y10T428/2982
    • The present invention relates to a poly (ester amide) (PEA) having a chemical formula described by structural formula (IV), wherein m+p varies from 0.9-0.1 and q varies from 0.1 to 0.9 m+p+q=1 whereby m or p could be 0 n is about 5 to about 300; (pref. 50-200) R1 is independently selected from the group consisting of (C2-C20) alkylene, (C2-C20) alkenylene, —(R9—CO—O—R10—O—CO—R9)—, —CHR11—O—CO—R12—COOCR11— and combinations thereof; R3 and R4 in a single backbone unit m or p, respectively, are independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C1-C6)alkyl, —(CH2)SH, —(CH2)2S(CH3), —CH2OH, —CH(OH)CH3, —(CH2)4NH3+, —(CH2)3NHC(═NH2+)NH2, —CH2COOH, —(CH2)COOH, —CH2—CO—NH2, —CH2CH2—CO—NH2, —CH2CH2COOH, CH3—CH2—CH(CH3)—, (CH3)2—CH—CH2—, H2N—(CH2)4—, Ph-CH2—, CH═C—CH2—, HO-p-Ph-CH2—, (CH3)2—CH—, Ph-NH—, NH—(CH2)3—C—, NH—CH═N—CH═C—CH2—. R5 is selected from the group consisting of (C2-C20)alkylene, (C2-C20)alkenylene, alkyloxy or oligoethyleneglycol R6 is selected from bicyclic-fragments of 1,4:3,6-dianhydrohexitols of structural formula (III); R7 is selected from the group consisting of (C6-C10)aryl (C1-C6)alkyl R8 is (CH2)4-; R9 or R10 are independently selected from C2-C12 alkylene or C2-C12 alkenylene. R11 or R12 are independently selected from H, methyl, C2-C12 alkylene or C2-C12 alkenylene whereby a is at least 0.05 and b is at least 0.05 and a+b=1.
    • 7. 发明授权
    • Biodegradable polyesteramide copolymers for drug delivery
    • US09963549B2
    • 2018-05-08
    • US14128839
    • 2012-06-25
    • Guy DraaismaGeorge Mihov
    • Guy DraaismaGeorge Mihov
    • C08G69/44A61K47/69C08L77/12C08J5/18A61K47/34A61K31/165
    • C08G69/44A61K31/165A61K47/34A61K47/6921C08J5/18C08J2377/12C08L77/12Y10T428/2982
    • The present invention relates to a poly (ester amide) (PEA) having a chemical formula described by structural formula (IV), wherein m+p varies from 0.9-0.1 and q varies from 0.1 to 0.9 m+p+q=1 whereby m or p could be 0 n is about 5 to about 300; (pref. 50-200) R1 is independently selected from the group consisting of (C2-C20) alkylene, (C2-C20) alkenylene, —(R9—CO—O—R10—O—CO—R9)—, —CHR11—O—CO—R12—COOCR11— and combinations thereof; R3 and R4 in a single backbone unit m or p, respectively, are independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C1-C6)alkyl, —(CH2)SH, —(CH2)2S(CH3), —CH2OH, —CH(OH)CH3, —(CH2)4NH3+, —(CH2)3NHC(═NH2+)NH2, —CH2COOH, —(CH2)COOH, —CH2—CO—NH2, —CH2CH2—CO—NH2, —CH2CH2COOH, CH3—CH2—CH(CH3)—, (CH3)2—CH—CH2—, H2N—(CH2)4—, Ph-CH2—, CH═C—CH2—, HO-p-Ph-CH2—, (CH3)2—CH—, Ph-NH—, NH—(CH2)3—C—, NH—CH═N—CH═C—CH2—. R5 is selected from the group consisting of (C2-C20)alkylene, (C2-C20)alkenylene, alkyloxy or oligoethyleneglycol R6 is selected from bicyclic-fragments of 1,4:3,6-dianhydrohexitols of structural formula (III); R7 is selected from the group consisting of (C6-C10)aryl (C1-C6)alkyl R8 is (CH2)4-; R9 or R10 are independently selected from C2-C12 alkylene or C2-C12 alkenylene. R11 or R12 are independently selected from H, methyl, C2-C12 alkylene or C2-C12 alkenylene whereby a is at least 0.05 and b is at least 0.05 and a+b=1.